EQUITIES

Robust. Fundamental. Dynamic.

Our teams exercise independent thought with high conviction, resulting in portfolios that we believe are well positioned to address our clients' challenges – all within robust risk control frameworks.

vd-icon_Currency_CashUSD

$237.1bn
Equities Assets Under Management

vd-icon_People_3_Group v3

153
Equities Investment
Professionals

vd-icon_Bulleye_Target v3

19
Average Years’ Financial
Industry Experience

As at 30 September 2024

<span class="notranslate">no data</span>

$237.1bn
Equities Assets Under Management

153
Equities Investment
Professionals

19
Average Years’ Financial
Industry Experience

As at 30 September 2024

We measure success by a single factor: client outcomes. As a pure asset manager, our sole mission is to deliver consistent long-term risk-adjusted returns that exceed our benchmarks and peers, regardless of the prevailing investment landscape.

Featured strategies

Global Life Sciences

By understanding the science and business of health care, our experienced team seeks to invest in companies addressing unmet medical needs or improving efficiencies.

Biotechnology Innovation

A biotechnology strategy that seeks to leverage a disciplined approach to identify compelling opportunities across the biotech landscape in both public and private investments

Global Technology Leaders

A global approach to investing in technology companies from a highly experienced team



Insights

Investing in a new Japan

Why have Japanese stocks become much more investable today?

Chart to Watch: Productivity rebound

A resurgence in productivity underscores a significant shift toward greater efficiency.

European espresso: Post-election reforms could re-energise a stagnating Germany

After years of stagnation, the collapse of the German coalition opens the door to structural reforms that could benefit the economy and stock markets.